To all Grey Horizon readers,
Blog postings will resume the week of June 1, 2021.
Thank you for your support. Take care and stay well.
Monday, 17 May 2021
Discovery of AMBRA1 suggests new cancer treatment strategies
Recent research by a joint collaborative effort between scientists in the United States and Europe have uncovered AMBRA1, a protein which functions as a tumour suppressor. As cancer is caused by innumerable cells that will not stop diving, thus forming a tumour, AMBRA1 "marks other proteins involved in helping cells divide...for destruction when cell division isn't needed." While additional research is needed to determine interactions present between AMBRA1 and cancer cells, these tumour suppressors can indeed be more prominent in one cancer versus another.
To learn more about this research, click here.
Monday, 10 May 2021
Brentuximab for children and teens with Hodgkin lymphoma
A new study conducted at St. Jude Children's Research Hospital indicates that "it may be possible to reduce or eliminate the need for radiation to treat advanced cancer in children and teens with Hodgkin lymphoma. According to study lead investigator Dr. Monika Metzger, 27 (35%) of the 77 patients involved in the trial did not require radiation treatments, thus suggesting that the findings "are an important first step in moving forward using even less radiation to treat high-risk pediatric Hodgkin lymphoma."
To read more about this study, click here.
Monday, 3 May 2021
Personalization of follow-up care needed to address varying health burdens in breast cancer patients
With breast cancer considered a largely curable disease (more than 70% of survivors live at least 10 years after diagnosis), quality of life care is seen as a key aspect in the patients cancer journey. At the recent ESMO Breast Cancer 2021 Virtual Congress, a study from the Netherlands Cancer Institute in Amsterdam showed that "breast cancer survivors differ widely in the burden of symptoms they experience after the end of treatment and thereby revealed an unmet need for tailored approaches to follow-up care." According to breast cancer expert Nadia Harbeck, patients "need to be well-informed and must be made to feel comfortable about contacting their physician outside of their planned consultations if necessary."
To read more about this study, click here.
Sources mentioned:
F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, I. T. Rubio, S. Zackrisson and E. Senkus. Early Breast Cancer: ESMO Clinical Practice Guidelines. https://doi.org/10.1093/annonc/mdz173
Abstract 134P_PR ‘Towards tailored follow-up care for breast cancer survivors: cluster analyses based on symptom burden’ will be available as e-Poster from Wednesday 5 May at 09:00 CEST. Annals of Oncology, Volume 32, Supplement 2, May 2021
Abstract 140P ‘How breast cancer recurrences are found? - a real-world, prospective cohort study’ will be available as e-Poster from Wednesday 5 May at 09:00 CEST. Annals of Oncology, Volume 32, Supplement 2, May 2021
Subscribe to:
Posts (Atom)